Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status.

Matthew J. Ellis(Guardant (United States)), William R. Miller(Houston Methodist), F. Jänicke, Erhard Quebe‐Fehling, Andrew Coop, Hilary A. Chaudri‐Ross(Novartis (Switzerland)), Tao Yu(Weifang Medical University), Baljit Singh, L. Mauriac(Institut Bergonié), Dean B. Evans(Novartis (Switzerland)), Antonio Llombart‐Cussac(MedSIR (Spain))

PubMed

October 1, 2003

Cited by 202

Related Papers

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

|Journal of Clinical Oncology|2017|1.7k

The molecular portraits of breast tumors are conserved across microarray platforms

|BMC Genomics|2006|1.5k

Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial

|Journal of Clinical Oncology|2001|1.1k

Whole-genome analysis informs breast cancer response to aromatase inhibition

|Nature|2012|1k

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

|JAMA Oncology|2019|983